We are live on
!
Find out more
MB
MPM BioImpact Portfolio holdings
AUM
$1.64B
1-Year Est. Return
245.64%
This Fund
S&P 500
This Quarter
Est. Return
-24.96%
1 Year Est. Return
+245.64%
3 Year Est. Return
+550.3%
5 Year Est. Return
+647.56%
10 Year Est. Return
–
AUM
$373M
AUM Growth
-$176M
(-32%)
Cap. Flow
-$17M
Cap. Flow
% of AUM
-4.55%
Top 10 Holdings %
Top 10 Hldgs %
67.37%
Holding
38
New
5
Increased
4
Reduced
17
Closed
1
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
RETA
Reata Pharmaceuticals, Inc. Class A Common Stock
RETA
|
+$5.34M |
| 2 |
Arcutis Biotherapeutics
ARQT
|
+$4.37M |
| 3 |
Phathom Pharmaceuticals
PHAT
|
+$3.12M |
| 4 |
Relmada Therapeutics
RLMD
|
+$2.85M |
| 5 |
TPTX
Turning Point Therapeutics, Inc. Common Stock
TPTX
|
+$2.69M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
LITS
Lite Strategy Inc
LITS
|
+$33M |
| 2 |
ITOS
iTeos Therapeutics
ITOS
|
+$3.59M |
| 3 |
BioCryst Pharmaceuticals
BCRX
|
+$367K |
| 4 |
Cytokinetics
CYTK
|
+$285K |
| 5 |
Crinetics Pharmaceuticals
CRNX
|
+$265K |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Healthcare | 100% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
|
EPIX
26
DELISTED
ESSA Pharma
EPIX
| $4.08M | 1.1% |
660,892
-7,796
| -1% | -$68.5K |
|
|
EPZM
27
DELISTED
Epizyme, Inc
EPZM
| $3.94M | 1.06% |
3,425,202
| – | – |
|
28
Revolution Medicines
RVMD
$44.6B
| $3.73M | 1% |
146,041
| – | – |
|
|
29
Relmada Therapeutics
RLMD
$462M
| $3.73M | 1% |
+138,000
| New | +$2.85M |
|
30
Acadia Pharmaceuticals
ACAD
$5.02B
| $3.67M | 0.99% |
151,750
+26,750
| +21% | +$647K |
|
|
AVDL
31
DELISTED
Avadel Pharmaceuticals
AVDL
| $2.82M | 0.76% |
412,363
+37,037
| +10% | +$255K |
|
|
32
Phathom Pharmaceuticals
PHAT
$743M
| $2.63M | 0.71% |
+193,326
| New | +$3.12M |
|
|
KRTX
33
DELISTED
Karuna Therapeutics, Inc. Common Stock
KRTX
| $2.54M | 0.68% |
+20,000
| New | +$2.25M |
|
34
NeoGenomics
NEO
$2.32B
| $1.65M | 0.44% |
135,573
-4,849
| -3% | -$102K |
|
|
INZY
35
DELISTED
Inozyme Pharma
INZY
| $1.21M | 0.32% |
294,980
-7,635
| -3% | -$44.9K |
|
|
TECX
36
Tectonic Therapeutic
TECX
$696M
| $855K | 0.23% |
53,993
| – | – |
|
37
Black Diamond Therapeutics
BDTX
$128M
| $664K | 0.18% |
239,888
| – | – |
|
|
LITS
38
Lite Strategy Inc
LITS
$33.4M
| – | – |
-617,549
| Closed | -$33M |
|
Similar funds
OCM
LFS
TIM
AAG
MRG
EPW
TWM
MA
MPM BioImpact's Q1 2022 Portfolio in Review
As of Q1 2022, MPM BioImpact held 38 positions worth $373M, down 32% from $549M the previous quarter. Its ten largest holdings account for 67% of the portfolio.
MPM BioImpact withdrew a net $17M in Q1 2022, closing 1 position and reducing 17 holdings. Its most notable exit was Lite Strategy Inc, an estimated $33M position sold in full.
By sector, the portfolio is most concentrated in Healthcare at 100% of assets, unchanged from a quarter earlier.
Against the trend, MPM BioImpact opened a new position in Reata Pharmaceuticals, Inc. Class A Common Stock worth $5.9M.
- MPM BioImpact's largest Q1 2022 buy was Reata Pharmaceuticals, Inc. Class A Common Stock: 180,000 shares worth $5.9M.
- MPM BioImpact added most to Turning Point Therapeutics, Inc. Common Stock in Q1 2022, an estimated $2.69M increase.
- MPM BioImpact's biggest Q1 2022 reduction was iTeos Therapeutics, cutting an estimated $3.59M.
- MPM BioImpact fully exited Lite Strategy Inc in Q1 2022, selling an estimated $33M.
- MPM BioImpact's ten largest holdings make up 67% of its $373M portfolio in Q1 2022.
- MPM BioImpact opened 5 new positions and closed 1 in Q1 2022.
- MPM BioImpact's portfolio value fell 32% quarter-over-quarter to $373M.
Based on MPM BioImpact's 13F filing for Q1 2022, filed 13 May 2022.